HK Stock Market Move | DUALITYBIO-B(09606) rose nearly 15% in the afternoon, and the B7-H3 ADC is expected to be included in a breakthrough therapy.

DUALITY BIO-B (09606) rose nearly 15% in the afternoon, rising 10.33% as of the time of publication to 238 Hong Kong dollars, with a trading volume of 318 million Hong Kong dollars. On the news front, on July 20, the CDE website showed that Ying En Biotech's DB-1311/BNT324 is intended to be included in a breakthrough therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after previous treatment with androgen receptor pathway inhibitors (ARPI) and taxane chemotherapy. Public information shows that DB-1311/BNT324 is an ADC targeting B7-H3 developed by Ying En Biotech. In 2023, BioNTech reached a partnership agreement with Ying En Biotech, obtaining overseas rights to Ying En's DB-1311 and DB-1303 drugs. On May 12, 2026, Ying En Biotech exercised its exclusive option to participate in sharing the research and development costs of DB-1311 in the United States region, as well as the profits and losses generated from the commercial operation of the drug.